Elevance Health Announces Appearance at UBS Global Healthcare Conference

INDIANAPOLIS--(BUSINESS WIRE)-- Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on November 12, at 7:15 a.m. Pacific Standard Time (PST) / 10:15 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the link here.

For those unable to listen to the live webcast, a replay will be available for 90 days following the presentation.

To listen to the live webcast, please visit Elevance Health’s website www.elevancehealth.com at least 15 minutes early to download and install any necessary audio software. Individuals who listen to the presentations will be presumed to have read Elevance Health’s recent filings with the SEC, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 113 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241105576784/en/

Investor Relations:
Stephen Tanal
[email protected]

Media Relations:
Leslie Porras
[email protected]

Source: Elevance Health, Inc.

You May Also Be Interested In

• NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting
• Quoin Pharmaceuticals reports interim Phase 2/3 data for QRX003
• Moderna prices $2.6B convertible notes offering due 2032